Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2019 17:37 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement

HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
August 05, 2019 16:15 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update

Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...
July 08, 2019 08:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...
June 17, 2019 06:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®

Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...

keyboard_arrow_left Previous Page